Research & Clinical Trials
Rhythm Pharmaceuticals' Setmelanotide Holds 18.8% BMI Reduction at Two Years in Hypothalamic Obesity
By News Desk ·
Key takeaways
- Patients on continuous setmelanotide averaged an 18.8% BMI reduction after two years, while those who switched from placebo averaged 16.5%.
- Of 125 patients entering the extension, 81 completed two years, including 54 on continuous drug and 27 who switched.
- AstraZeneca made an offer of about $10 billion to acquire Rhythm Pharmaceuticals, Reuters reported earlier in November 2026.
Rhythm Pharmaceuticals said on November 16, 2026 that setmelanotide produced clinically meaningful weight reduction in patients with a rare form of obesity caused by brain damage after two years of therapy. Yahoo carried the report. The company was testing the drug, approved by the US FDA as Imcivree, in adult and pediatric patients with acquired hypothalamic obesity and a type of genetic obesity.
How the Setmelanotide Extension Trial Ran
The long-term data were presented at ObesityWeek 2026 in Washington, D.C. In the trial, 142 participants aged 4 years and older were randomly assigned to setmelanotide or placebo for the first year, after which everyone continuing into the long-term extension received setmelanotide.
Of the 125 patients who entered the extension, 81 completed two years of treatment, including 54 who received continuous setmelanotide and 27 who switched from placebo after the first year. Patients treated continuously achieved an average 18.8% reduction in body mass index after two years, while those who switched saw an average 16.5% reduction.
Acquired hypothalamic obesity is a rare neuroendocrine disease that causes excess and sustained weight gain after injuries such as tumor growth or stroke in the brain. Setmelanotide is designed to activate the MC4R pathway in the brain to reduce excessive hunger and help the body burn more energy. The company said the safety profile was generally consistent with previous trials in acquired hypothalamic obesity patients. In the second year, 52 of the 125 participants had treatment-related side effects, none classified as serious, and one death was reported and deemed unrelated to treatment.
Rhythm's Regulatory and Funding Record
Rhythm Pharmaceuticals is a Boston-based company founded in 2008 that develops therapies for rare diseases of the MC4R pathway, according to akta.pro company records. The FDA approved IMCIVREE for acquired hypothalamic obesity in adults and pediatric patients aged 4 and older in March 2026, the first-ever FDA-approved therapy for the indication, supported by an 18.4% placebo-adjusted BMI reduction in the Phase 3 TRANSCEND trial. The same records list a $750 million post-IPO debt round in November 2026 led by HealthCare Royalty Partners and full-year 2025 revenue of $194 million, representing 50% growth over 2024.
Rhythm's Path to the Two-Year Readout
Rhythm launched IMCIVREE in Japan for acquired hypothalamic obesity in October 2026, following MHLW approval and NHI price-list inclusion, Stock Titan reported. The drug is the first approved therapy for the condition in Japan, where an estimated 5,000 to 8,000 patients live. In November 2026, the Wall Street Journal reported that AstraZeneca made a roughly $10 billion offer to buy Rhythm Pharmaceuticals, paying $124 per share, in a deal that would expand AstraZeneca's portfolio of rare disease treatments.
What Comes Next for Rhythm
Rhythm reported positive preliminary Phase 2 results for setmelanotide in Prader-Willi syndrome in December 2025, covering 18 patients with BMI and hyperphagia reductions at 3 and 6 months, and said it plans to advance the program to Phase 3.